TDC A/S
1.11.2021 13:53:18 CET | Globenewswire | Press release
TDC will conduct a conference call for investors and analysts on November 5, 2021 at 14.30 CET to present the Q3 2021 results. Lasse Pilgaard, Chief Financial Officer in TDC, Henrik Hjortshøj-Nielsen, Head of Treasury and Investor Relations in TDC, Andreas Pfister, Chief Executive Officer in TDC NET and Jon James, Chief Executive Officer in Nuuday, will comment on the results and answer questions during the conference call.
The investor and analyst conference will be available in Microsoft Teams at:
Dial in to Microsoft Teams is: +45 32 72 51 67 – Code: 860 676 939#
The conference call will refer to a slide deck that will be available from November 5, 2021 at approx. 10.00 CET on the link:
https://tdcgroup.com/en/investor-relations
Please mute your microphone before and during the presentation.
For inquiries regarding the above please contact TDC Investor Relations on +45 2921 1749 or investorrelations@tdc.dk.
TDC tickers
Reuters TDC.CO.
Bloomberg TDC DC.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV23.3.2026 07:30:00 CET | Press release
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
Sampo plc23.3.2026 07:30:00 CET | Press release
Sampo has received approval for its extended Group Partial Internal Model
Basilea Pharmaceutica International Ltd, Allschwil23.3.2026 07:15:00 CET | Press release
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Novartis Pharma AG23.3.2026 07:15:00 CET | Press release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
CoaguSense, Inc.23.3.2026 07:00:00 CET | Press release
CoaguSense Announces Agreement to Acquire DOASENSE DOAC Testing Business, Expanding Leadership in Anticoagulation Monitoring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
